|Bid||17.10 x 4000|
|Ask||17.29 x 800|
|Day's range||16.62 - 17.37|
|52-week range||12.75 - 23.11|
|Beta (5Y monthly)||1.55|
|PE ratio (TTM)||142.25|
|Earnings date||27 Jul 2020 - 31 Jul 2020|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||27 Jun 2007|
|1y target est||22.07|
On May 29, 2020, Delaware Enhanced Global Dividend and Income Fund (NYSE: DEX) (the "Fund"), a closed-end fund, paid a monthly distribution on its common stock of $0.0714 per share to shareholders of record at the close of business on May 22, 2020.
Today, Delaware Enhanced Global Dividend and Income Fund (NYSE: DEX) (the "Fund"), a New York Stock Exchange–listed closed-end fund trading under the symbol "DEX," announced that, effective May 19, 2020, Allan Saustrup Jensen will be appointed as co-manager for the Fund. Mr. Jensen will join Damon J. Andres, Åsa Annerstedt, Wayne A. Anglace, Adam H. Brown, Liu-Er Chen, Craig C. Dembek, Roger A. Early, Chris Gowlland, Jens Hansen, Claus Juul, Nikhil G. Lalvani, Paul A. Matlack, John P. McCarthy, Klaus Petersen, and Babak (Bob) Zenouzi in making day-to-day investment decisions for the Fund.
Pfizer (NYSE: PFE) will look like a much different company within a few months as it spins off Upjohn and merges the unit with Mylan. Bristol Myers Squibb (NYSE: BMY) is still integrating Celgene after acquiring the biotech in November. Both Pfizer and BMS have seen their stocks plunge close to 30% this year then make strong rebounds.
ROE helps investors distinguish profit-generating companies from profit burners and is useful in determining the financial health of a company.
Mylan (NASDAQ: MYL) announced on Tuesday that it has entered into a global partnership with Gilead Sciences (NASDAQ: GILD) to manufacture and distribute remdesivir in 127 low- and middle-income countries as a treatment for COVID-19. Because of the urgent nature of the pandemic, Gilead has indicated its desire to make remdesivir widely available as quickly as possible, and partnering with Mylan will help it accomplish that goal. The pharmaceutical companies have worked together for 15 years in their efforts to fight other infectious diseases including HIV and hepatitis C. Remdesivir is the 10th drug licensed by Gilead to Mylan.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
You might say that Mylan (NASDAQ: MYL) is a company in waiting. At some point over the next few months, its merger with Pfizer's Upjohn will close. Mylan will be no more; a new company named Viatris will be created from the merger.
Mylan (MYL) delivered earnings and revenue surprises of 2.27% and -2.17%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Pfizer (NYSE: PFE) will lower its dividend payout at some point later this year for a straightforward reason. The pharma giant plans to spin off its Upjohn unit and merge it with Mylan (NASDAQ: MYL). The transaction will form a new entity that will be known as Viatris.
Joining us on the call today from Revance is President and Chief Executive Officer Mark Foley, Chief Financial Officer Toby Schilke, Chief Operating Officer and President of R&D and Product Operations Dr. Abhay Joshi and Chief Commercial Officer of Aesthetics and Therapeutics Dustin Sjuts. Earlier today, Revance released financial results for the first quarter ended March 31, 2020.
Theravance (TBPH) reports wider- than-expected loss in the first quarter of 2020 while sales beat estimates. The company reiterates 2020 outlook.
Investors will look forward to regular top and bottom-line numbers and updates on the merger with Upjohn, when Mylan (MYL) reports Q1 results.
NEW YORK, April 30, 2020 -- FGL Holdings (FG) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in.
HERTFORDSHIRE, England , PITTSBURGH and BENGALURU, India , April 28, 2020 /CNW/ -- Mylan N.V. and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced the launch of Fulphila®, a biosimilar to Neulasta® (pegfilgrastim). Fulphila is approved by Health Canada to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-neoplastic drugs.
The European Commission said on Wednesday it had approved generic drugmaker Mylan NV's <MYL.O> planned purchase of Pfizer's <PFE.N> off-patient branded drugs business Upjohn, subject to conditions. The Commission, which oversees competition policy in the European Union, said its investigation had focused on genericised medicines, which are sold to pharmacies and hospitals, with overlaps in a number of fields. Mylan and Upjohn have offered to divest Mylan's certain generic medicines across 20 countries in the European Economic Area and the United Kingdom, the Commission said.
WILMINGTON, Del., April 21, 2020 -- Rigrodsky & Long, P.A. announces that it is investigating: Opus Bank (NASDAQ GS: OPB) regarding possible breaches of fiduciary duties.
Mylan (MYL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Generic drugmaker Mylan NV <MYL.O> has offered concessions to address European Union antitrust concerns about its bid for Pfizer's <PFE.N> off-patent branded drugs business Upjohn, a filing on the European Commission site showed on Monday. U.S. drugmaker Pfizer announced the deal in July as part of a strategy allowing it to focus on its more profitable newer medicines. The European Commission set an April 22 deadline for its decision after Mylan put in its offer on March 27.